Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Inhibitex, Inc.

http://www.inhibitex.com

Latest From Inhibitex, Inc.

FDA’s Novel Approvals Again Led By Oncology And Neurology, But Dermatology Also Shone In 2022

Pink Sheet infographic breaks down the trends and surprises in 2022 approvals. Cancer therapies and non-malignant hematology exceeded the average use of expedited review programs but were weighted to orphan diseases, while dermatology saw first-in-class approvals for big markets.

Pink Sheet Perspectives Approvals

Is Lecanemab Plus t-PA A Deadly Combination? One Case Study May Shed Light

A letter in the New England Journal of Medicine suggests the death of one extension trial participant treated with t-PA may have been caused by lecanemab, but a response notes fatal intracerebral hemorrhages have been seen after t-PA in certain patients in the absence of anti-amyloid drugs.

Clinical Trials Drug Safety

Is Lecanemab Plus t-PA A Deadly Combination? One Case Study May Shed Light

A letter in the New England Journal of Medicine suggests the death of one extension trial participant treated with t-PA may have been caused by lecanemab, but a response notes fatal intracerebral hemorrhages have been seen after t-PA in certain patients in the absence of anti-amyloid drugs.

Clinical Trials Drug Safety

Cardiovascular Catch-Up: Cardiac Implants Puts Ring Around Tricuspid Annulus; Boston Scientific’s Acurate neo2 TAVR Progresses; Medtronic Promotes New Stroke Plan

This edition of Medtech Insight’s regular round-up of some recent cardiovascular technology news and conversations you may have missed, including updates from Cardiac Implants, Boston Scientific, HeartBeam and Medtronic.

Cardiovascular Approvals
See All

Company Information

UsernamePublicRestriction

Register